344 related articles for article (PubMed ID: 34499330)
21. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Mannelli F; Guglielmelli P; Fazi P; Crea E; Piciocchi A; Vignetti M; Amadori S; Pane F; Venditti A; Vannucchi AM
Future Oncol; 2023 Jan; 19(2):103-111. PubMed ID: 36651780
[TBL] [Abstract][Full Text] [Related]
22. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS; Class CA; Montalban-Bravo G; Wei Y; Sasaki K; Naqvi K; Ganan-Gomez I; Yang H; Soltysiak KA; Kanagal-Shamanna R; Do KA; Kantarjian HM; Garcia-Manero G
Leuk Lymphoma; 2020 Jun; 61(6):1493-1499. PubMed ID: 32036728
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
[TBL] [Abstract][Full Text] [Related]
24. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
25. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
26. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
27. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
28. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
29. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
Kloos A; Mintzas K; Winckler L; Gabdoulline R; Alwie Y; Jyotsana N; Kattre N; Schottmann R; Scherr M; Gupta C; Adams FF; Schwarzer A; Heckl D; Schambach A; Imren S; Humphries RK; Ganser A; Thol F; Heuser M
Leukemia; 2020 Nov; 34(11):2951-2963. PubMed ID: 32576961
[TBL] [Abstract][Full Text] [Related]
30. Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Ogata H; Okamoto I; Yoshimoto G; Obara T; Ijichi K; Iwama E; Harada T; Akashi K; Nakanishi Y
Respir Investig; 2017 Mar; 55(2):181-183. PubMed ID: 28274536
[TBL] [Abstract][Full Text] [Related]
31. Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.
Coltro G; Patnaik MM
Curr Oncol Rep; 2019 Nov; 21(11):101. PubMed ID: 31728739
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
33. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
34. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
35. Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
Zhang T; Zhou H; Xu M; Qian C; Sun A; Wu D; Xue S
Ann Hematol; 2023 Apr; 102(4):973-975. PubMed ID: 36745193
[No Abstract] [Full Text] [Related]
36. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract][Full Text] [Related]
37. Chronic myelomonocytic leukemia - a review.
Thomopoulos TP; Bouhla A; Papageorgiou SG; Pappa V
Expert Rev Hematol; 2021 Jan; 14(1):59-77. PubMed ID: 33275852
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
39. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.
Patnaik MM; Wassie EA; Lasho TL; Hanson CA; Ketterling R; Tefferi A
Am J Hematol; 2015 May; 90(5):411-6. PubMed ID: 25645147
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
